

COVID-19 Impact on Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C6551C991FC2EN.html>

Date: July 2020

Pages: 159

Price: US\$ 3,900.00 (Single User License)

ID: C6551C991FC2EN

Abstracts

This report focuses on the global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Cox-2 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Boehringer-Ingelheim

TerSera Therapeutics

Iroko Pharmaceuticals

Apotex

Yung Shin Pharmaceutical

Breckenridge Pharmaceutical

Meda Pharmaceuticals

Cipla

Glenmark Pharmaceuticals

Teva

PuraCap Pharmaceutical

Almirall Limited

Lupin Pharmaceuticals

Aurobindo Pharma

Pfizer

Mylan

Takeda

Bayer

Novacap

Abbott

Geri-Care

Perrigo

Kopran

Merck

Hengrui pharmaceutical

Kelun Group

Qilu Pharmaceutical

Taro Pharmaceuticals

Market segment by Type, the product can be split into

Meloxicam

Celecoxib

Etoricoxib

Imrecoxib

Etodolac

Parecoxib

Other

Market segment by Application, split into

Rheumatoid Arthritis

Osteoarthritis

Spondylosis Chronica Ankylopoietica

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players.

To present the Selective Cox-2 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Selective Cox-2 Inhibitors are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
- 1.4 Market Analysis by Type
 - 1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 Meloxicam
 - 1.4.3 Celecoxib
 - 1.4.4 Etoricoxib
 - 1.4.5 Imrecoxib
 - 1.4.6 Etodolac
 - 1.4.7 Parecoxib
 - 1.4.8 Other
- 1.5 Market by Application
 - 1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
 - 1.5.2 Rheumatoid Arthritis
 - 1.5.3 Osteoarthritis
 - 1.5.4 Spondylosis Chronica Ankylopoietica
 - 1.5.5 Other
- 1.6 Coronavirus Disease 2019 (Covid-19): Selective Cox-2 Inhibitors Industry Impact
 - 1.6.1 How the Covid-19 is Affecting the Selective Cox-2 Inhibitors Industry
 - 1.6.1.1 Selective Cox-2 Inhibitors Business Impact Assessment - Covid-19
 - 1.6.1.2 Supply Chain Challenges
 - 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products
 - 1.6.2 Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
 - 1.6.3 Measures / Proposal against Covid-19
 - 1.6.3.1 Government Measures to Combat Covid-19 Impact
 - 1.6.3.2 Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Selective Cox-2 Inhibitors Market Perspective (2015-2026)

2.2 Selective Cox-2 Inhibitors Growth Trends by Regions

2.2.1 Selective Cox-2 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Selective Cox-2 Inhibitors Historic Market Share by Regions (2015-2020)

2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

2.3.5 Selective Cox-2 Inhibitors Market Growth Strategy

2.3.6 Primary Interviews with Key Selective Cox-2 Inhibitors Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Selective Cox-2 Inhibitors Players by Market Size

3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2015-2020)

3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2015-2020)

3.1.3 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Selective Cox-2 Inhibitors Market Concentration Ratio

3.2.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2019

3.3 Selective Cox-2 Inhibitors Key Players Head office and Area Served

3.4 Key Players Selective Cox-2 Inhibitors Product Solution and Service

3.5 Date of Enter into Selective Cox-2 Inhibitors Market

3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2015-2020)

4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2021-2026)

5 SELECTIVE COX-2 INHIBITORS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

- 6.1 North America Selective Cox-2 Inhibitors Market Size (2015-2020)
- 6.2 Selective Cox-2 Inhibitors Key Players in North America (2019-2020)
- 6.3 North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 6.4 North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

7 EUROPE

- 7.1 Europe Selective Cox-2 Inhibitors Market Size (2015-2020)
- 7.2 Selective Cox-2 Inhibitors Key Players in Europe (2019-2020)
- 7.3 Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 7.4 Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

8 CHINA

- 8.1 China Selective Cox-2 Inhibitors Market Size (2015-2020)
- 8.2 Selective Cox-2 Inhibitors Key Players in China (2019-2020)
- 8.3 China Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 8.4 China Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

9 JAPAN

- 9.1 Japan Selective Cox-2 Inhibitors Market Size (2015-2020)
- 9.2 Selective Cox-2 Inhibitors Key Players in Japan (2019-2020)
- 9.3 Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 9.4 Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

- 10.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2015-2020)
- 10.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 10.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

11 INDIA

- 11.1 India Selective Cox-2 Inhibitors Market Size (2015-2020)

- 11.2 Selective Cox-2 Inhibitors Key Players in India (2019-2020)
- 11.3 India Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 11.4 India Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

- 12.1 Central & South America Selective Cox-2 Inhibitors Market Size (2015-2020)
- 12.2 Selective Cox-2 Inhibitors Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
- 12.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

- 13.1 Boehringer-Ingelheim
 - 13.1.1 Boehringer-Ingelheim Company Details
 - 13.1.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
 - 13.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
 - 13.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.1.5 Boehringer-Ingelheim Recent Development
- 13.2 TerSera Therapeutics
 - 13.2.1 TerSera Therapeutics Company Details
 - 13.2.2 TerSera Therapeutics Business Overview and Its Total Revenue
 - 13.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
 - 13.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.2.5 TerSera Therapeutics Recent Development
- 13.3 Iroko Pharmaceuticals
 - 13.3.1 Iroko Pharmaceuticals Company Details
 - 13.3.2 Iroko Pharmaceuticals Business Overview and Its Total Revenue
 - 13.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
 - 13.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.3.5 Iroko Pharmaceuticals Recent Development
- 13.4 Apotex
 - 13.4.1 Apotex Company Details
 - 13.4.2 Apotex Business Overview and Its Total Revenue

- 13.4.3 Apotex Selective Cox-2 Inhibitors Introduction
- 13.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
- 13.4.5 Apotex Recent Development
- 13.5 Yung Shin Pharmaceutical
 - 13.5.1 Yung Shin Pharmaceutical Company Details
 - 13.5.2 Yung Shin Pharmaceutical Business Overview and Its Total Revenue
 - 13.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
 - 13.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.5.5 Yung Shin Pharmaceutical Recent Development
- 13.6 Breckenridge Pharmaceutical
 - 13.6.1 Breckenridge Pharmaceutical Company Details
 - 13.6.2 Breckenridge Pharmaceutical Business Overview and Its Total Revenue
 - 13.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
 - 13.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.6.5 Breckenridge Pharmaceutical Recent Development
- 13.7 Meda Pharmaceuticals
 - 13.7.1 Meda Pharmaceuticals Company Details
 - 13.7.2 Meda Pharmaceuticals Business Overview and Its Total Revenue
 - 13.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
 - 13.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.7.5 Meda Pharmaceuticals Recent Development
- 13.8 Cipla
 - 13.8.1 Cipla Company Details
 - 13.8.2 Cipla Business Overview and Its Total Revenue
 - 13.8.3 Cipla Selective Cox-2 Inhibitors Introduction
 - 13.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.8.5 Cipla Recent Development
- 13.9 Glenmark Pharmaceuticals
 - 13.9.1 Glenmark Pharmaceuticals Company Details
 - 13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
 - 13.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
 - 13.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 13.9.5 Glenmark Pharmaceuticals Recent Development
- 13.10 Teva
 - 13.10.1 Teva Company Details

- 13.10.2 Teva Business Overview and Its Total Revenue
- 13.10.3 Teva Selective Cox-2 Inhibitors Introduction
- 13.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
- 13.10.5 Teva Recent Development
- 13.11 PuraCap Pharmaceutical
 - 10.11.1 PuraCap Pharmaceutical Company Details
 - 10.11.2 PuraCap Pharmaceutical Business Overview and Its Total Revenue
 - 10.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
 - 10.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.11.5 PuraCap Pharmaceutical Recent Development
- 13.12 Almirall Limited
 - 10.12.1 Almirall Limited Company Details
 - 10.12.2 Almirall Limited Business Overview and Its Total Revenue
 - 10.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
 - 10.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.12.5 Almirall Limited Recent Development
- 13.13 Lupin Pharmaceuticals
 - 10.13.1 Lupin Pharmaceuticals Company Details
 - 10.13.2 Lupin Pharmaceuticals Business Overview and Its Total Revenue
 - 10.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
 - 10.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.13.5 Lupin Pharmaceuticals Recent Development
- 13.14 Aurobindo Pharma
 - 10.14.1 Aurobindo Pharma Company Details
 - 10.14.2 Aurobindo Pharma Business Overview and Its Total Revenue
 - 10.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
 - 10.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.14.5 Aurobindo Pharma Recent Development
- 13.15 Pfizer
 - 10.15.1 Pfizer Company Details
 - 10.15.2 Pfizer Business Overview and Its Total Revenue
 - 10.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
 - 10.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.15.5 Pfizer Recent Development
- 13.16 Mylan
 - 10.16.1 Mylan Company Details

- 10.16.2 Mylan Business Overview and Its Total Revenue
- 10.16.3 Mylan Selective Cox-2 Inhibitors Introduction
- 10.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
- 10.16.5 Mylan Recent Development
- 13.17 Takeda
 - 10.17.1 Takeda Company Details
 - 10.17.2 Takeda Business Overview and Its Total Revenue
 - 10.17.3 Takeda Selective Cox-2 Inhibitors Introduction
 - 10.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.17.5 Takeda Recent Development
- 13.18 Bayer
 - 10.18.1 Bayer Company Details
 - 10.18.2 Bayer Business Overview and Its Total Revenue
 - 10.18.3 Bayer Selective Cox-2 Inhibitors Introduction
 - 10.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.18.5 Bayer Recent Development
- 13.19 Novacap
 - 10.19.1 Novacap Company Details
 - 10.19.2 Novacap Business Overview and Its Total Revenue
 - 10.19.3 Novacap Selective Cox-2 Inhibitors Introduction
 - 10.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.19.5 Novacap Recent Development
- 13.20 Abbott
 - 10.20.1 Abbott Company Details
 - 10.20.2 Abbott Business Overview and Its Total Revenue
 - 10.20.3 Abbott Selective Cox-2 Inhibitors Introduction
 - 10.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.20.5 Abbott Recent Development
- 13.21 Geri-Care
 - 10.21.1 Geri-Care Company Details
 - 10.21.2 Geri-Care Business Overview and Its Total Revenue
 - 10.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
 - 10.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.21.5 Geri-Care Recent Development
- 13.22 Perrigo
 - 10.22.1 Perrigo Company Details
 - 10.22.2 Perrigo Business Overview and Its Total Revenue
 - 10.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
 - 10.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020)

- 10.22.5 Perrigo Recent Development
- 13.23 Kopran
 - 10.23.1 Kopran Company Details
 - 10.23.2 Kopran Business Overview and Its Total Revenue
 - 10.23.3 Kopran Selective Cox-2 Inhibitors Introduction
 - 10.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.23.5 Kopran Recent Development
- 13.24 Merck
 - 10.24.1 Merck Company Details
 - 10.24.2 Merck Business Overview and Its Total Revenue
 - 10.24.3 Merck Selective Cox-2 Inhibitors Introduction
 - 10.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.24.5 Merck Recent Development
- 13.25 Hengrui pharmaceutical
 - 10.25.1 Hengrui pharmaceutical Company Details
 - 10.25.2 Hengrui pharmaceutical Business Overview and Its Total Revenue
 - 10.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
 - 10.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.25.5 Hengrui pharmaceutical Recent Development
- 13.26 Kelun Group
 - 10.26.1 Kelun Group Company Details
 - 10.26.2 Kelun Group Business Overview and Its Total Revenue
 - 10.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
 - 10.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.26.5 Kelun Group Recent Development
- 13.27 Qilu Pharmaceutical
 - 10.27.1 Qilu Pharmaceutical Company Details
 - 10.27.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
 - 10.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
 - 10.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
 - 10.27.5 Qilu Pharmaceutical Recent Development
- 13.28 Taro Pharmaceuticals
 - 10.28.1 Taro Pharmaceuticals Company Details
 - 10.28.2 Taro Pharmaceuticals Business Overview and Its Total Revenue
 - 10.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Introduction
 - 10.28.4 Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)

10.28.5 Taro Pharmaceuticals Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

- Table 1. Selective Cox-2 Inhibitors Key Market Segments
- Table 2. Key Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
- Table 3. Ranking of Global Top Selective Cox-2 Inhibitors Manufacturers by Revenue (US\$ Million) in 2019
- Table 4. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026
- Table 5. Key Players of Meloxicam
- Table 6. Key Players of Celecoxib
- Table 7. Key Players of Etoricoxib
- Table 8. Key Players of Imrecoxib
- Table 9. Key Players of Etodolac
- Table 10. Key Players of Parecoxib
- Table 11. Key Players of Other
- Table 12. COVID-19 Impact Global Market: (Four Selective Cox-2 Inhibitors Market Size Forecast Scenarios)
- Table 13. Opportunities and Trends for Selective Cox-2 Inhibitors Players in the COVID-19 Landscape
- Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 15. Key Regions/Countries Measures against Covid-19 Impact
- Table 16. Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
- Table 17. Global Selective Cox-2 Inhibitors Market Size Growth by Application (US\$ Million): 2020 VS 2026
- Table 18. Global Selective Cox-2 Inhibitors Market Size by Regions (US\$ Million): 2020 VS 2026
- Table 19. Global Selective Cox-2 Inhibitors Market Size by Regions (2015-2020) (US\$ Million)
- Table 20. Global Selective Cox-2 Inhibitors Market Share by Regions (2015-2020)
- Table 21. Global Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026) (US\$ Million)
- Table 22. Global Selective Cox-2 Inhibitors Market Share by Regions (2021-2026)
- Table 23. Market Top Trends
- Table 24. Key Drivers: Impact Analysis
- Table 25. Key Challenges
- Table 26. Selective Cox-2 Inhibitors Market Growth Strategy
- Table 27. Main Points Interviewed from Key Selective Cox-2 Inhibitors Players

Table 28. Global Selective Cox-2 Inhibitors Revenue by Players (2015-2020) (Million US\$)

Table 29. Global Selective Cox-2 Inhibitors Market Share by Players (2015-2020)

Table 30. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2019)

Table 31. Global Selective Cox-2 Inhibitors by Players Market Concentration Ratio (CR5 and HHI)

Table 32. Key Players Headquarters and Area Served

Table 33. Key Players Selective Cox-2 Inhibitors Product Solution and Service

Table 34. Date of Enter into Selective Cox-2 Inhibitors Market

Table 35. Mergers & Acquisitions, Expansion Plans

Table 36. Global Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 37. Global Selective Cox-2 Inhibitors Market Size Share by Type (2015-2020)

Table 38. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2021-2026)

Table 39. Global Selective Cox-2 Inhibitors Market Size Share by Application (2015-2020)

Table 40. Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US\$)

Table 41. Global Selective Cox-2 Inhibitors Market Size Share by Application (2021-2026)

Table 42. North America Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US\$)

Table 43. North America Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)

Table 44. North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 45. North America Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 46. North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US\$)

Table 47. North America Selective Cox-2 Inhibitors Market Share by Application (2015-2020)

Table 48. Europe Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US\$)

Table 49. Europe Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)

Table 50. Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 51. Europe Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 52. Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
(Million US\$)

Table 53. Europe Selective Cox-2 Inhibitors Market Share by Application (2015-2020)

Table 54. China Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US\$)

Table 55. China Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)

Table 56. China Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 57. China Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 58. China Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
(Million US\$)

Table 59. China Selective Cox-2 Inhibitors Market Share by Application (2015-2020)

Table 60. Japan Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US\$)

Table 61. Japan Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)

Table 62. Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 63. Japan Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 64. Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
(Million US\$)

Table 65. Japan Selective Cox-2 Inhibitors Market Share by Application (2015-2020)

Table 66. Southeast Asia Key Players Selective Cox-2 Inhibitors Revenue (2019-2020)
(Million US\$)

Table 67. Southeast Asia Key Players Selective Cox-2 Inhibitors Market Share
(2019-2020)

Table 68. Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
(Million US\$)

Table 69. Southeast Asia Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 70. Southeast Asia Selective Cox-2 Inhibitors Market Size by Application
(2015-2020) (Million US\$)

Table 71. Southeast Asia Selective Cox-2 Inhibitors Market Share by Application
(2015-2020)

Table 72. India Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US\$)

Table 73. India Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)

Table 74. India Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 75. India Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 76. India Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

(Million US\$)

Table 77. India Selective Cox-2 Inhibitors Market Share by Application (2015-2020)

Table 78. Central & South America Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US\$)

Table 79. Central & South America Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)

Table 80. Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US\$)

Table 81. Central & South America Selective Cox-2 Inhibitors Market Share by Type (2015-2020)

Table 82. Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US\$)

Table 83. Central & South America Selective Cox-2 Inhibitors Market Share by Application (2015-2020)

Table 84. Boehringer-Ingelheim Company Details

Table 85. Boehringer-Ingelheim Business Overview

Table 86. Boehringer-Ingelheim Product

Table 87. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 88. Boehringer-Ingelheim Recent Development

Table 89. TerSera Therapeutics Company Details

Table 90. TerSera Therapeutics Business Overview

Table 91. TerSera Therapeutics Product

Table 92. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 93. TerSera Therapeutics Recent Development

Table 94. Iroko Pharmaceuticals Company Details

Table 95. Iroko Pharmaceuticals Business Overview

Table 96. Iroko Pharmaceuticals Product

Table 97. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 98. Iroko Pharmaceuticals Recent Development

Table 99. Apotex Company Details

Table 100. Apotex Business Overview

Table 101. Apotex Product

Table 102. Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 103. Apotex Recent Development

Table 104. Yung Shin Pharmaceutical Company Details

Table 105. Yung Shin Pharmaceutical Business Overview

Table 106. Yung Shin Pharmaceutical Product

Table 107. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 108. Yung Shin Pharmaceutical Recent Development

Table 109. Breckenridge Pharmaceutical Company Details

Table 110. Breckenridge Pharmaceutical Business Overview

Table 111. Breckenridge Pharmaceutical Product

Table 112. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 113. Breckenridge Pharmaceutical Recent Development

Table 114. Meda Pharmaceuticals Company Details

Table 115. Meda Pharmaceuticals Business Overview

Table 116. Meda Pharmaceuticals Product

Table 117. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 118. Meda Pharmaceuticals Recent Development

Table 119. Cipla Business Overview

Table 120. Cipla Product

Table 121. Cipla Company Details

Table 122. Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 123. Cipla Recent Development

Table 124. Glenmark Pharmaceuticals Company Details

Table 125. Glenmark Pharmaceuticals Business Overview

Table 126. Glenmark Pharmaceuticals Product

Table 127. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 128. Glenmark Pharmaceuticals Recent Development

Table 129. Teva Company Details

Table 130. Teva Business Overview

Table 131. Teva Product

Table 132. Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 133. Teva Recent Development

Table 134. PuraCap Pharmaceutical Company Details

Table 135. PuraCap Pharmaceutical Business Overview

Table 136. PuraCap Pharmaceutical Product

Table 137. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business

(2015-2020) (Million US\$)

Table 138. PuraCap Pharmaceutical Recent Development

Table 139. Almirall Limited Company Details

Table 140. Almirall Limited Business Overview

Table 141. Almirall Limited Product

Table 142. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 143. Almirall Limited Recent Development

Table 144. Lupin Pharmaceuticals Company Details

Table 145. Lupin Pharmaceuticals Business Overview

Table 146. Lupin Pharmaceuticals Product

Table 147. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 148. Lupin Pharmaceuticals Recent Development

Table 149. Aurobindo Pharma Company Details

Table 150. Aurobindo Pharma Business Overview

Table 151. Aurobindo Pharma Product

Table 152. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 153. Aurobindo Pharma Recent Development

Table 154. Pfizer Company Details

Table 155. Pfizer Business Overview

Table 156. Pfizer Product

Table 157. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 158. Pfizer Recent Development

Table 159. Mylan Company Details

Table 160. Mylan Business Overview

Table 161. Mylan Product

Table 162. Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 163. Mylan Recent Development

Table 164. Takeda Company Details

Table 165. Takeda Business Overview

Table 166. Takeda Product

Table 167. Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 168. Takeda Recent Development

Table 169. Bayer Company Details

Table 170. Bayer Business Overview

Table 171. Bayer Product

Table 172. Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 173. Bayer Recent Development

Table 174. Novacap Company Details

Table 175. Novacap Business Overview

Table 176. Novacap Product

Table 177. Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 178. Novacap Recent Development

Table 179. Abbott Company Details

Table 180. Abbott Business Overview

Table 181. Abbott Product

Table 182. Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 183. Abbott Recent Development

Table 184. Geri-Care Company Details

Table 185. Geri-Care Business Overview

Table 186. Geri-Care Product

Table 187. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 188. Geri-Care Recent Development

Table 189. Perrigo Company Details

Table 190. Perrigo Business Overview

Table 191. Perrigo Product

Table 192. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 193. Perrigo Recent Development

Table 194. Kopran Company Details

Table 195. Kopran Business Overview

Table 196. Kopran Product

Table 197. Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 198. Kopran Recent Development

Table 199. Merck Company Details

Table 200. Merck Business Overview

Table 201. Merck Product

Table 202. Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

US\$)

Table 203. Merck Recent Development

Table 204. Hengrui pharmaceutical Company Details

Table 205. Hengrui pharmaceutical Business Overview

Table 206. Hengrui pharmaceutical Product

Table 207. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 208. Hengrui pharmaceutical Recent Development

Table 209. Kelun Group Company Details

Table 210. Kelun Group Business Overview

Table 211. Kelun Group Product

Table 212. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 213. Kelun Group Recent Development

Table 214. Qilu Pharmaceutical Company Details

Table 215. Qilu Pharmaceutical Business Overview

Table 216. Qilu Pharmaceutical Product

Table 217. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 218. Qilu Pharmaceutical Recent Development

Table 219. Taro Pharmaceuticals Company Details

Table 220. Taro Pharmaceuticals Business Overview

Table 221. Taro Pharmaceuticals Product

Table 222. Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US\$)

Table 223. Taro Pharmaceuticals Recent Development

Table 224. Research Programs/Design for This Report

Table 225. Key Data Information from Secondary Sources

Table 226. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Selective Cox-2 Inhibitors Market Share by Type: 2020 VS 2026
- Figure 2. Meloxicam Features
- Figure 3. Celecoxib Features
- Figure 4. Etoricoxib Features
- Figure 5. Imrecoxib Features
- Figure 6. Etodolac Features
- Figure 7. Parecoxib Features
- Figure 8. Other Features
- Figure 9. Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
- Figure 10. Rheumatoid Arthritis Case Studies
- Figure 11. Osteoarthritis Case Studies
- Figure 12. Spondylosis Chronica Ankylopoietica Case Studies
- Figure 13. Other Case Studies
- Figure 14. Selective Cox-2 Inhibitors Report Years Considered
- Figure 15. Global Selective Cox-2 Inhibitors Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 16. Global Selective Cox-2 Inhibitors Market Share by Regions: 2020 VS 2026
- Figure 17. Global Selective Cox-2 Inhibitors Market Share by Regions (2021-2026)
- Figure 18. Porter's Five Forces Analysis
- Figure 19. Global Selective Cox-2 Inhibitors Market Share by Players in 2019
- Figure 20. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2019)
- Figure 21. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2019
- Figure 22. North America Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 23. Europe Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 24. China Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 25. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 26. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 27. India Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million

US\$)

Figure 28. Central & South America Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US\$)

Figure 29. Boehringer-Ingelheim Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 31. TerSera Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 33. Iroko Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 35. Apotex Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 37. Yung Shin Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 39. Breckenridge Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 41. Meda Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 43. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 45. Glenmark Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 46. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 47. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business

(2015-2020)

Figure 49. PuraCap Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 50. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 51. Almirall Limited Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 52. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 53. Lupin Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 54. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 55. Aurobindo Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 56. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 57. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 58. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 59. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 60. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 61. Takeda Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 62. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 63. Bayer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 64. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 65. Novacap Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 66. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 67. Abbott Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 68. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

I would like to order

Product name: COVID-19 Impact on Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C6551C991FC2EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6551C991FC2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

